Viridian Therapeutics Inc 1S1
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 1S1 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,236.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 94
Comparables
Valuation
|
Metric
|
1S1
|
VOR
|
CTIC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.16 | 0.64 | — |
Price/Sales | 2,236.90 | — | 14.71 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
1S1
|
VOR
|
CTIC
|
|---|---|---|---|
Quick Ratio | 23.47 | 8.13 | 1.20 |
Current Ratio | 23.99 | 8.46 | 1.27 |
Interest Coverage | −104.84 | — | −3.20 |
Quick Ratio
1S1
VOR
CTIC
Profitability
|
Metric
|
1S1
|
VOR
|
CTIC
|
|---|---|---|---|
Return on Assets (Normalized) | −35.08% | −48.29% | −46.52% |
Return on Equity (Normalized) | −65.95% | −61.06% | — |
Return on Invested Capital (Normalized) | −42.29% | −54.20% | −143.40% |
Return on Assets
1S1
VOR
CTIC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bcbhcstp | Nntnycr | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Htqvgtqzj | Xmnmls | $114.2 Bil | |||
| Moderna Inc
MRNA
| Chlhffxp | Gsx | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Sknpdlxr | Pqq | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rggdjrn | Smll | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ghvtdfxd | Lgnfkj | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wsfmbwh | Kwzwng | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Gpmrjkxy | Vpnj | $12.8 Bil | |||
| Incyte Corp
INCY
| Bxnqspfm | Lcrmgvg | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tscmqwrjz | Sxjywt | $12.2 Bil |